Understanding double-hit DLBCL

The exact diagnostic name can depend on the genes involved and the classification system used by the pathology team. The phrase signals lymphoma biology that may influence treatment planning; it does not describe two separate cancers or two physical blows to the body.

A specialist examines biopsy tissue to identify the lymphoma type. Protein stains can show MYC and BCL2 expression, but a double-expressor pattern on staining is not the same as double-hit disease. Genetic testing is needed to identify the relevant rearrangements and distinguish these categories.

This distinction matters because rearrangements can indicate faster-growing behaviour and may lead the multidisciplinary team to consider a different treatment approach or closer response assessment. Age, fitness, disease sites, blood results, and personal priorities remain part of the decision.

Ask for the integrated pathology diagnosis and whether MYC, BCL2, and BCL6 were examined with appropriate genetic tests. Check whether any result is pending and whether a lymphoma-pathology review is needed. Discuss the aim, expected benefits, burdens, and monitoring plan for the recommended therapy. Before treatment starts, tell the team about infections, heart or nerve problems, regular medicines, supplements, and any previous cancer treatment.

Promptly report a lump that is enlarging quickly, increasing abdominal fullness, persistent fever, drenching night sweats, new weakness, or worsening pain. Once therapy begins, follow the centre's instructions for fever and use its urgent number for shaking chills, breathlessness, repeated vomiting, severe diarrhoea, reduced urine, or unusual bleeding. Call emergency services for severe breathing difficulty, chest pain, collapse, confusion, or bleeding that cannot be controlled.

You could ask: Which gene rearrangements were found? How is double-hit different from double-expressor lymphoma in my report? Has the biopsy had specialist review? Why do you recommend this treatment, and how will response be measured? What alternatives would be considered if the lymphoma does not respond or later returns?